MAPK1 and familial pancreatic carcinoma: RIPK4 was shown to activate the CRAF-MEK-ERK pathway by promoting the degradation of proteasome-mediated phosphatidylethanolamine binding protein 1 (PEBP1) in pancreatic cancer [190].